Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
August 9, 2016 6:50 AM EDT
-- Bendeka market share grows to 80% --
-- Positive FDA
meeting on Ryanodex for EHS --
-- Eagle purchases Ryanodex
royalty --
-- Announces $75 million share repurchase
program --
-- Q2 EPS increases to $0.84 per basic and $0.80
per diluted, Total Revenue $40.9 million --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:
Business Highlights:... More
Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
August 9, 2016 6:45 AM EDT-- Hajj Study Results Sufficient for Human Data in Filing --
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
-- Only Completion of Ongoing Animal Studies Required for Submission--
-- Eagle Purchases Royalty Rights to Ryanodex Portfolio --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals (Eagle or the Company) (NASDAQ: EGRX) today announced that the U.S. Food and Drug Administration ("FDA") has determined that no additional human safety and efficacy data is required for the... More
